RO7496353 + Atezolizumab + Capecitabine + S-1 + Nivolumab + Oxaliplatin + Nab-paclitaxel + Gemcitabine
Phase 1Active 1 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-small Cell Lung Cancer
Conditions
Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma
Trial Timeline
Oct 2, 2023 → Jun 30, 2026
NCT ID
NCT05867121About RO7496353 + Atezolizumab + Capecitabine + S-1 + Nivolumab + Oxaliplatin + Nab-paclitaxel + Gemcitabine
RO7496353 + Atezolizumab + Capecitabine + S-1 + Nivolumab + Oxaliplatin + Nab-paclitaxel + Gemcitabine is a phase 1 stage product being developed by Chugai Pharmaceutical for Non-small Cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05867121. Target conditions include Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma.
What happened to similar drugs?
20 of 20 similar drugs in Non-small Cell Lung Cancer were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
6
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05867121 | Phase 1 | Active |
Competing Products
20 competing products in Non-small Cell Lung Cancer